Company Overview of Karolinska Institutet
Karolinska Institutet is a Swedish university, which specializes in medicine. Several companies in the field of medicine and biotechnology have been founded as a result of the university's research programmes. As a result, Karolinska Institutet cooperates closely with the private sector and has created an investment arm (Karolinska Investment Fund) in order to enhance its scientists' innovations. Founded in 1810, the company is headquartered in Stockholm.
Founded in 1810
46 8 728 64 00
46 8 31 11 01
Key Executives for Karolinska Institutet
Professor of Environmental Toxicology
Professor of Pharmacology
Professor of Neurobiology
Compensation as of Fiscal Year 2015.
Karolinska Institutet Key Developments
Ferring Pharmaceuticals and Karolinska Institutet Sign Collaboration Agreement for Establishment of a Research Center Exploiting the Human Microbiome
Jan 27 16
Ferring Pharmaceuticals and Karolinska Institutet announced that a collaboration agreement has been signed for the establishment of a research center exploiting the human microbiome. The programme will be fully funded by Ferring Pharmaceuticals and governed by a joint steering committee. The proposed project focuses on therapeutic areas where Ferring has extensive expertise. Karolinska Institutet has a deep understanding of the human microbiome. Parts of the research will be carried out at the Science for Life Laboratory (SciLifeLab) that provides access to a broad technical platform for studying complex microbiological communities in well-defined human material. The collaboration between the two partners form a solid foundation for the ambition of a better understanding of the contribution of the human microbiome to physiology and pathophysiology and opens opportunities for development of novel therapies. The research will be led by Professor Lars Engstrand, Karolinska Institutet, who will serve as director. The center will further establish an internationally competitive infrastructure with focus on translational research in the microbiome field set up to develop a comprehensive mapping of the human microbiome in health and disease.
Sorrento and Karolinska Institutet Establish Exclusive Partnership for Research and Development of Natural Killer Cell-based Therapies
Jan 11 16
Sorrento Therapeutics, Inc. announced that it has formed an exclusive partnership with the Karolinska Institutet in Stockholm, Sweden, to perform cutting-edge immuno-oncology research and to develop new natural killer (NK) cell-based therapies. Under the agreement, Sorrento will sponsor preclinical and clinical research & development programs focused on NK biology as well as adoptive NK cell therapies and, in return, obtain full rights to the resulting discoveries and developments. The research will be performed at KI, but there will also be an active research exchange with Sorrento R&D in San Diego. A joint steering committee with members from both Sorrento and KI will guide the program activities.
Karolina Institute Presents at UBS Greater China Conference 2016, Jan-11-2016 12:30 PM
Nov 20 15
Karolina Institute Presents at UBS Greater China Conference 2016, Jan-11-2016 12:30 PM. Venue: Pudong Shangri-La Hotel, 33 Fu Cheng Road, Pudong, Shanghai, 200120, China. Speakers: Hans Rosling, Professor.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries